Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients

BACKGROUND: Peptide vaccines offer the opportunity to elicit glioma-specific T cells with tumor killing ability. Using antigens eluted from the surface of glioblastoma samples, we designed a phase I/II study to test safety and immunogenicity of the IMA950 multipeptide vaccine adjuvanted with poly-IC...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Migliorini, Denis, Dutoit, Valérie, Allard, Mathilde, Grandjean Hallez, Nicole, Marinari, Eliana, Widmer, Valérie, Philippin, Géraldine, Corlazzoli, Francesca, Gustave, Robin, Kreutzfeldt, Mario, Blazek, Nathalie, Wasem, Joëlle, Hottinger, Andreas, Koka, Avinash, Momjian, Shahan, Lobrinus, Alexander, Merkler, Doron, Vargas, Maria-Isabel, Walker, Paul R, Patrikidou, Anna, Dietrich, Pierre-Yves
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6620642/
https://ncbi.nlm.nih.gov/pubmed/30753611
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz040
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados